|
OI at baseline
|
|
Yes
|
182
|
53.3
|
|
No
|
208
|
46.7
|
|
Functional status (age ≥5 year) (N = 262)
|
|
Working
|
150
|
57.3
|
|
Ambulatory
|
105
|
40.1
|
|
Bedridden
|
7
|
2.7
|
|
Developmental History (age < 5 years) (N = 128)
|
|
Appropriate
|
97
|
75.8
|
|
Delayed
|
24
|
17.8
|
|
Regressive
|
7
|
5.5
|
|
WHO clinical stage
|
|
Stage I and II
|
229
|
58.8
|
|
Stage III and IV
|
161
|
41.2
|
|
Past TB test before ART
|
|
Not determined
|
310
|
79.5
|
|
Negative
|
37
|
9.5
|
|
Positive
|
43
|
11.0
|
|
Past TB treatment
|
|
No treatment
|
346
|
88.7
|
|
2SRHZ/4RH
|
30
|
7.7
|
|
2HRZES/4HRE
|
3
|
0.8
|
|
HRZE/4RH
|
11
|
2.8
|
|
CD4 count or percent
|
|
Below the threshold
|
273
|
70.0
|
|
Above the threshold
|
117
|
30.0
|
|
Hemoglobin level
|
|
< 10 g/dl
|
47
|
12.0
|
|
≥10 g/dl
|
343
|
88.0
|
|
ART eligibility criteria
|
|
Immunologic/ CD4
|
107
|
27.9
|
|
WHO clinical stage
|
47
|
12.0
|
|
Both clinical and immunologic
|
152
|
39.0
|
|
Without criteria
|
84
|
21.5
|
|
Type of Regimen during follow up
|
|
4a = d4t-3TC-NVP
|
48
|
12.3
|
|
4b = d4t-3TC-EFV
|
22
|
5.6
|
|
4c = AZT-3TC-NVP
|
149
|
38.2
|
|
4d = AZT-3TC-EFV
|
78
|
20.0
|
|
1e = TDF-3TC-EFV
|
35
|
9.0
|
|
1 h = ABC-3TC-NVP
|
10
|
2.6
|
|
1 g = ABC-3TC-EFV
|
13
|
3.3
|
|
2nd line
|
9
|
2.3
|
|
Others
|
26
|
6.7
|
|
OI during follow-up
|
|
Yes
|
107
|
27.4
|
|
No
|
283
|
72.6
|
|
Cotrimoxazole preventive therapy
|
|
Yes
|
233
|
59.7
|
|
No
|
157
|
40.3
|
|
Regimen change during follow-up
|
|
Yes
|
118
|
30.3
|
|
No
|
272
|
69.7
|
|
Regimen stopped during follow-up
|
|
Yes
|
18
|
4.6
|
|
No
|
372
|
95.4
|
|
ART adherence in the 1st 3 months
|
|
Good /fair
|
495
|
92.2
|
|
Poor
|
42
|
7.8
|
